Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and...

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Clinical Trials

Background:

• Patients with acute coronary syndrome (ACS) face risks of peripheral artery disease (PAD) and venous thromboembolism (VTE).
• PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors effectively lower lipoprotein(a) and LDL-C.
• The study investigates the impact of PCSK9 inhibition on PAD and VTE events post-ACS.

Purpose of the Study:

• To determine if PCSK9 inhibition reduces PAD events and VTE in ACS patients.
• To explore the relationship between these reductions and levels of lipoprotein(a) and LDL-C.

Main Methods:

• A prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial involving 18,924 ACS patients.
• Patients received either the PCSK9 inhibitor alirocumab or placebo, alongside statin therapy.
• PAD events (critical limb ischemia, revascularization, amputation) and VTE (DVT, PE) were assessed, with LDL-C corrected for lipoprotein(a).

Main Results:

• Alirocumab significantly reduced PAD events (HR, 0.69; P=0.004) and showed a trend towards reducing VTE (HR, 0.67; P=0.06).
• PAD event reduction was linked to baseline lipoprotein(a) levels, not LDL-C.
• Changes in lipoprotein(a) with alirocumab, but not LDL-C, correlated with VTE risk.

Conclusions:

• In ACS patients on statins, alirocumab reduces PAD events, especially in those with high lipoprotein(a).
• Further investigation is warranted to confirm alirocumab's effect on VTE risk and its relation to lipoprotein(a).
• The study registered under NCT01663402 provides key insights into PCSK9 inhibition's role in cardiovascular outcomes.